Sentences with phrase «patient response to chemotherapy»
This Team is studying vitamin D receptors to determine if it is an effective «super-enhancer» which improves patient response to chemotherapy.
https://pancreaticcancercollective.org/ Not exact matches
When the team compared their results to previously published clinical and genomic data, they found that their model successfully predicted patients» chemotherapy response more than 80 percent of the time.
The researchers discovered that patients who had certain genetic variations in interleukin genes had a better response to either surgery or chemotherapy, resulting in improvements in overall survival, disease - free survival and the amount of time until disease recurred.
Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90 % disease control and 59 % response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1
Findings based on this new technology are likely to have a profound impact on improving the detection and diagnosis of diseased cells and in evaluating a patient's response to chemotherapy.
Patients were categorized into those who had a good response and those who had a poor response to chemotherapy, based on a recently approved chemotherapy response score that correlates with progression - free and overall survival.
If it would be possible to identify tumours that have an aberrantly stabilised SOX9 protein, the drugs tested in this study could be used to prevent tumour spread in these patients and improve their response to standard chemotherapy.
In 2006 Potti's team published several papers in high - profile journals reporting that certain gene expression signatures predicted a patient's response to chemotherapy.
«The next step is to test tumors from more human patients and see how the results compare to the response that the patients have to chemotherapy,» said Walsh.
«We found very high response rates to this treatment combination, which has the added benefit of having a much reduced risk of long - term organ damage compared to the highly toxic chemotherapy agents typically used for patients with relapsed Hodgkin lymphoma,» says Dr. Kelly, who is Program Director of the Pediatric Hematology / Oncology Service Line at the Women & Children's Hospital of Buffalo and holds an additional faculty appointment with the University at Buffalo.
In the Phase II clinical trial, Dr. Miller and colleagues in the National Cancer Institute - supported Gynecologic Oncology Group found that in patients who had not received prior chemotherapy, the combination cocktail had a 31 percent response rate for up to 7 months, and an overall survival of 12 months.
In addition to helping patients live longer, more patients treated with pembrolizumab responded to treatment and for a longer duration than those treated with chemotherapy; the objective response rate — the percentage of patients whose tumours shrank or disappeared — was almost twice as high with pembrolizumab: 21 % compared to 11 % on chemotherapy.
The median duration of response for patients who responded to pembrolizumab has not been reached, while the median duration of response for patients who responded to chemotherapy was only 4.3 months.
In a study reported recently in the journal Scientific Reports, a team centered at Tokyo Medical and Dental University (TMDU) identified two molecules that can improve the response of pancreatic cancer to a common chemotherapy drug and also predict the prognosis of pancreatic cancer patients.
The researchers are now conducting an individual patient analysis to correlate response to chemotherapy with the fall in VEGFR receptor levels in the blood.
Today, The New York Times reports that on Sunday Duke decided to halt enrollment in three clinical trials in which Potti and Duke's Joseph Nevins were using gene - expression signatures to predict a patient's response to chemotherapy.
Pauling denied that the study was a replication of Cameron's experiment because the patients used in the Mayo trial had all received chemotherapy before taking vitamin C so their negative response to treatment with vitamin C may have had more to do with their depressed immune system than the inefficacy of vitamin C.
Evidence also suggests that platinum - based chemotherapies are superior therapies regardless of the patient's previous response to treatment.
«Predicting response to chemotherapy for triple - negative breast cancer patients: New method.»
In nonmetastatic triple - negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery.
In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).
That the quality of the tumor's blood vessels could dictate the patient's response to chemotherapy could be one reason that two patients with similar cancers respond differently to the same therapy.
ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.
To assess these responses in well defined cohorts of M. tuberculosis - infected or exposed individuals and patients with active TB either or not co-infected with HIV, and follow up longitudinally after anti-tuberculosis chemotherapy, in order to correlate specific responses with protective immunitTo assess these responses in well defined cohorts of M. tuberculosis - infected or exposed individuals and patients with active TB either or not co-infected with HIV, and follow up longitudinally after anti-tuberculosis chemotherapy, in order to correlate specific responses with protective immunitto correlate specific responses with protective immunity.
Investigators led by Edward S. Kim, MD, of MD Anderson Cancer Center in Houston, initiated the SELECT trial after earlier, phase II studies showed that cetuximab improved response rates when added to chemotherapy regimens for patients with recurrent or progressive NSCLC.
De La Cruz LM, McDonald E, Mick R, Datta J, Nocera NF, Czerniecki BJ: Anti-HER2 TH1 response is superior to breast MRI in predicting response to neoadjuvant chemotherapy in patients with HER2 positive breast cancer Annals of Surgical Oncology 24 (4): 1057 - 1063,2017.
If it would be possible to identify tumors that have an aberrantly stabilized SOX9 protein, caused by inactivation of FBW7, the drugs tested in this study could be used to prevent tumor spread in these patients and improve their response to standard chemotherapy.
Addition of bevacizumab to standard chemotherapy in the neoadjuvant setting in patients with HER2 - negative metastatic breast cancer improves progression - free survival and the proportion of patients achieving pathological complete response.
But these epigenetic drugs have shown some success in improving patients» response to chemotherapy or immunotherapy, or in overcoming resistance to those standard treatments.
A biopsy of each patient's cancer will be screened for 600 genes as well as protein expression to uncover molecules and pathways that are driving the cancer and to predict a patient's response to chemotherapy or other tailored therapy.
Patients with stage V lymphoma tend to have a poor response to chemotherapy and it may be helpful to stage the patient to rule out whether or not the patient is in Stage V.